期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

类风湿关节炎联合药物治疗评价 被引量：2

Evaluation of Combination Therapy for Rheumatoid Arthritis
下载PDF
导出
摘要 目前,针对类风湿关节炎的药物治疗,主张在早期诊断的基础上尽早应用改善病情的抗风湿药。已有研究证明,联合应用2种或2种以上改善病情的抗风湿药,在疾病控制的各个方面均体现出显著优越性。现将对联合治疗中药物选择、用药策略,以及临床工作中面临的疗效、对象选择、早期诊断等问题予以综述。 Currently, the most acceptable medical treatment strategy for rheumatoid arthritis is the early application of the disease modifying antirheumatic drugs to the premise of the early diagnosis. Some studies have shown the significant superiority of the combination therapy in all aspects of the disease control. This article provides an overview of the choice of the drugs, the strategy of the treatment in the combination therapy, the problems in the efficacy, and selection of the patients and early diagnosis in clinical practice.
作者 段明达 戴生明
机构地区 第二军医大学附属长海医院风湿免疫科
出处 《医学综述》 2008年第8期1239-1242,共4页 Medical Recapitulate
基金 上海市浦江人才计划(06PJ14121) 全军医药卫生研究基金资助(06Q45)
关键词 类风湿关节炎 联合药物治疗 早期诊断 Rheumatoid arthritis Combination therapy Early diagnosis
分类号 R593.22 [医药卫生—内科学]
  • 相关文献

参考文献16

  • 1van der Horst-Bruinsma IE, Speyer I, Visser H, et al. Diagnosis and course of early-onset arthritis : results of a special early arthritis clinic compared with routine patient care [ J ]. Br J Rheumatol, 1998,37 (10) : 1084-1088.
  • 2O'Dell JR. Therapeutic strategies for rheumatoid arthritis [ J ]. N Engl J Med,2004,350(25 ) :2591-2602.
  • 3Mottoncn T, Hannoncn P, Korpcla M, et al. Delay to institation of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthrltis[J]. Arthritis Rheum,2002,46(4) :894-898.
  • 4Nell VP,Machold KP,Ebrel G,et al. Benefit of very early referral and very early therapy with disease modifying antirheumatic drugs in patients with early rheumatoid arthritis [ J ]. Rheumatology (Oxford) ,2004,43(7) :906-914.
  • 5Smolen JS, Aletaha D, Keystone E. Superior efficacy of combination therapy for rheumatoid arthritis[ J]. Arthritis Rheum ,2005,52 (10) :2975-2583.
  • 6Suresh E, Lambert CM. Combination treatment strategies in early rheumatoid arthritis [ J ]. Ann Rheum Dis, 2005, 64 ( 9 ) : 1252-1256.
  • 7Calguneri M, Pay S, Caliskaner Z, et al. Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis[ J ]. Clin Exp Rheumatol, 1999,17 (6) :699-704.
  • 8Breedveld FC,Weisman MH, Kavanaugh AF, et al. THE PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not previous methotrexate treatment [ J ]. Arthritis Rheum .2006.54( 1 ) :26-37.
  • 9Klareskog L,van der Heljde D,de jager JP,et al. TEMPO( trial of etanereept and methotrexate with radiographic outcomes)study investigators. Therapeutic effect of the combination of etanereept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis : double-blind randomized controlled trial [ J ]. Lancet.2004.363 ( 9410 ) :675 -681.
  • 10Ferraccoill GF, Gremese E,Tomletto P ,et al. Analysis of improvements, full responses, remissionand toxicity in rheumatoid patients treated with step-up combination therapy (mathotraxate, cyclosporine A, sulphasalazine) or monotherapy for three years [ J ]. Rheumatology (Oxford) ,2002,41(8) :892-898.

二级参考文献12

  • 1Van Jaarsveld CH,Jacobs JW,van der Veen MJ,et al.Aggressive treatment in early rheumatoid arthritis:a randomised controlled trial:on behalf of the rheumatic research foundation utrecht,the Netherlands. Ann Rheum Dis,2000,59:468-477.
  • 2Bukhari M,Lunt M,Harrison BJ,et al. Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis:results from the Norfolk Arthritis Register Study,a large inception cohort. Arthritis Rheum,2002,46:906-91
  • 3Barrett EM,Symmons DPM,Scott DGI.Employment attrition in a community based inception cohort of rheumatoid arthritis patients.Br J Rheumatol, 1996,35(Suppl):235.
  • 4Arend WP.The pathophysiology and treatment of rheumatoid arthritis. Arthritis Rheum, 1997,40:595-597.
  • 5Jorgensen C,Sun R,Rossi JF,et al. Expression of a multidrug resistance gene in human rheumatoid synovium. Rheumatol Int, 1995,15:83-86.
  • 6Calguneri M,Pay S,Caliskaner Z,et al. Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis.Clin Exp Rheumatol,1999,17:699-704.
  • 7Boers M,Verhoeven AC,Markusse HM,et al. Randomised comparison of combined step-down prednisolone,methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet, 1997,350:309-318.
  • 8Tugwell P.Combination therapy in rheumatoid arthritis:meta-analysis.J Rheumatol, 1996,44(Suppl):43-46.
  • 9Albers JM,Paimela L,Kurki P,et al. Treatment strategy,disease activity,and outcome in four cohorts of patients with early rheumatoid arthritis. Ann Rheum Dis,2001,60:453-458.
  • 10Van der Heijde DM.Radiographic imaging: the′gold standard' for assessment of disease progression in rheumatoid arthritis. Rheumatology (Oxford),2000,39(Suppl 1):9-16.

共引文献8

同被引文献18

  • 1戴俐明,陈学广,徐叔云.白芍总甙对实验性肝炎的保护作用[J].中国药理学通报,1993,9(6):449-453. 被引量：63
  • 2魏艳秋.白芍总苷治疗类风湿关节炎的临床观察[J].现代医药卫生,2005,21(13):1709-1709. 被引量：5
  • 3Smolen J S, Landew6 R, Breedveld F C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs[J]. Ann Rheum Dis, 2010,69(6) :964-975.
  • 4NamJ L, Winthrop K L, vanVollenhovenRF, etal. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA[J]. Ann Rheum Dis, 2010, 69(6): 976-986.
  • 5Bathon J M, Martin R W, Fleisehmann R M, et al. A com- parison of etanercept and methotrexate in patients with early rheumatoid arthritis[J]. N Engl J Med, 2000,343(22):1586- 1593.
  • 6Kameda H, Kanbe K, Sato E, et al. Continuation of metho trexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis:52-week results from the JESMR study [J]. J Rheumatol, 2011,38(8):1585-1592.
  • 7Smolen J S, Aletaha D, Bijlsma J W J, etal. Treating rheu- matoid arthritis to target & recommendations of an international task force[J]. Ann Rheum Dis, 2010,69(4):631-637.
  • 8Fleischmann R, Yoeum D. Does safety make a difference in selecting the right TNF antagonist? [J]. Arthritis Res Ther, 2004, 6(Suppl 2) :S12-S18.
  • 9Salmon-Ceron D, Tubach F, Lortholary O, et al. Drug specific risk of non-tuberculosis opportunistic infections in pa- tients receiving anti-TNF therapy reported to the 3-year pro- spective French RATIO registry[J]. Ann Rheum Dis, 2011, 70(4) :616-623.
  • 10Tubach F, Salmon D, Ravaud P, etal. Risk of tuberculosis is higher with anti tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry[J]. Arthritis Rheum, 2009, 60(7) :1884 -1894.

引证文献2

二级引证文献3

医学综述
2008年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部